PharmAla Data to be Published in ACS Chemical Neuroscience
VANCOUVER, British Columbia, Feb. 20, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased that data from its computational Drug Discovery program, in conjunction with the University of Waterloo (laboratory of Dr. James Gauld) and made possible by funding from MITACS, will be published in the scientific journal ACS Chemical Neuroscience this week. The article “Exploring Structure-Activity Relationships in Phenethylamines: A Path to Novel Mental Health Therapies” investigates the essential aspects of how the structure of phenethylamine molecules relates to their activity. It focuses on identifying key targets that are crucial for optimizing the safety and effectiveness of these compounds.
Related news for (MDXXF)
- PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
- PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
- PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
- PharmAla Closes Private Placement and Concurrent Debt Settlement
- PharmAla Announces Private Placement and Concurrent Debt Settlement